With €27M at launch, Vico revives Prosensa oligonucleotide programs, aims to edit RNA for Rett

With two RNA manipulation platforms united under one roof, Dutch biotech Vico will deploy its new series A round for clinical development of a program founder and Chairman Luc Dochez knows well from his time at Prosensa.

Vico Therapeutics B.V. said Wednesday it had raised €27 million

Read the full 461 word article

How to gain access

Continue reading with a
two-week free trial.